Buspirone tablets for generalized anxiety disorder management

Buspirone hydrochloride tablets are prescription antianxiety medications used primarily to manage generalized anxiety disorder (GAD) or provide short-term relief of anxiety symptoms. They belong to a class of drugs distinct from benzodiazepines and do not produce sedation, muscle relaxation, or anticonvulsant effects commonly seen with those agents.

Buspirone hydrochloride tablets are approved for treating anxiety disorders diagnosed as Generalized Anxiety Disorder (GAD) in adults. They relieve persistent anxiety and associated symptoms such as muscle tension, autonomic hyperactivity, apprehensive worry, and difficulty concentrating. The medication is intended for outpatients and has been evaluated mainly in patients with symptoms lasting from one month to over a year.

Buspirone is also used for short-term relief of anxiety symptoms. Anxiety related to everyday stress typically does not require anxiolytic treatment.

Buspirone hydrochloride

Buspirone's exact mechanism is not fully understood. It differs from typical anxiolytics by lacking sedative, muscle relaxant, and anticonvulsant actions. Buspirone binds with high affinity to serotonin 5-HT1A receptors in the brain and has moderate affinity for dopamine D2 receptors. It does not affect benzodiazepine receptors or the GABA neurotransmitter system. This profile suggests buspirone modulates serotonin and dopamine systems, which may contribute to its anxiolytic effects.

Buspirone hydrochloride tablets are administered orally in doses tailored to the patient's needs. Tablets come in 5 mg, 10 mg, 15 mg, and 30 mg strengths. The 5 mg and 10 mg tablets are scored for halving, and the 15 mg and 30 mg tablets can be halved or trisected to provide flexible dosing increments such as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, and 30 mg.

Patients should take buspirone consistently with regard to food (always with or always without) due to food's impact on drug absorption. Doses are usually divided multiple times per day according to medical direction. Dose adjustments should be guided by clinical assessment, especially if combined with drugs affecting buspirone metabolism.

Buspirone hydrochloride tablets are contraindicated in individuals with known hypersensitivity to buspirone.

Use with or within 14 days of stopping a monoamine oxidase inhibitor (MAOI) is contraindicated due to risks of serotonin syndrome or elevated blood pressure. Initiation of buspirone in patients treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated.

The use of buspirone is contraindicated in patients with hypersensitivity to the drug and in those currently taking or within 14 days of stopping monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome and/or hypertension. Starting buspirone during treatment with reversible MAOIs (e.g., linezolid or IV methylene blue) is also contraindicated.

Serotonin syndrome is a potentially life-threatening condition that can occur when buspirone is used alone or with other serotonergic or antidopaminergic drugs. Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, seizures, and gastrointestinal symptoms. Immediate discontinuation and supportive treatment are required if serotonin syndrome occurs.

Buspirone should not be substituted for antipsychotic agents since it lacks antipsychotic activity.

Buspirone generally causes less sedation than other anxiolytics. Some patients may experience dizziness, headache, nausea, or restlessness (akathisia-like symptoms). Withdrawal from previous CNS depressants like benzodiazepines should be gradual to avoid rebound anxiety or withdrawal symptoms such as irritability, insomnia, or tremors.

Buspirone is metabolized mainly by CYP3A4. Concomitant use with strong CYP3A4 inhibitors like erythromycin, itraconazole, verapamil, diltiazem, and nefazodone significantly increases buspirone plasma levels, which may enhance adverse effects. Dose reduction of buspirone is recommended when used with these drugs.

CYP3A4 inducers such as rifampin reduce buspirone concentrations and may require buspirone dose increase to maintain efficacy.

Co-administration with MAOIs, reversible MAOIs (linezolid, IV methylene blue), serotonergic agents (including triptans), or serotonin precursors should be avoided due to serotonin syndrome risk.

Buspirone does not significantly alter plasma levels of amitriptyline or diazepam but may increase minor side effects when combined with diazepam.

Patients should avoid large amounts of grapefruit juice as it markedly increases buspirone levels.

Patients should inform their healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding before using buspirone. Specific recommendations regarding use during pregnancy and lactation are not detailed in this labeling.